BEXXAR

Adverse Events

Drug Profile

Learn More

Reference

About Results

Comments

Bexxar Adverse Events Reported to the FDA Over Time

How are Bexxar adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Bexxar, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Bexxar is flagged as the suspect drug causing the adverse event.

Most Common Bexxar Adverse Events Reported to the FDA

What are the most common Bexxar adverse events reported to the FDA?

Pyrexia	25 (3.4%)
Fatigue	19 (2.58%)
Drug Ineffective	16 (2.17%)
Dyspnoea	16 (2.17%)
Nausea	16 (2.17%)
Arthralgia	14 (1.9%)
Chills	14 (1.9%)
Rash	14 (1.9%)
Hypotension	13 (1.77%)
Disease Progression	11 (1.49%)
Pain In Extremity	11 (1.49%)
	Show More
Pneumonia	11 (1.49%)
White Blood Cell Count Decreased	11 (1.49%)
Asthenia	9 (1.22%)
Back Pain	9 (1.22%)
Neutropenia	9 (1.22%)
Pruritus	9 (1.22%)
Chest Pain	8 (1.09%)
Dizziness	8 (1.09%)
Flushing	8 (1.09%)
Infusion Related Reaction	8 (1.09%)
Weight Decreased	8 (1.09%)
Cough	7 (.95%)
Platelet Count Decreased	7 (.95%)
Tremor	7 (.95%)
Cardiac Failure Congestive	6 (.82%)
Erythema	6 (.82%)
Feeling Hot	6 (.82%)
Lymphoma	6 (.82%)
Oedema	6 (.82%)
Oedema Peripheral	6 (.82%)
Pain	6 (.82%)
Thrombocytopenia	6 (.82%)
Abdominal Pain Upper	5 (.68%)
Chest Discomfort	5 (.68%)
Death	5 (.68%)
Dysgeusia	5 (.68%)
Infection	5 (.68%)
Syncope	5 (.68%)
Vomiting	5 (.68%)
Abdominal Distension	4 (.54%)
Acute Myeloid Leukaemia	4 (.54%)
Anaphylactic Reaction	4 (.54%)
Cellulitis	4 (.54%)
Depression	4 (.54%)
Groin Pain	4 (.54%)
Headache	4 (.54%)
Herpes Zoster	4 (.54%)
Hyperaesthesia	4 (.54%)
Hyperbilirubinaemia	4 (.54%)
Hyperthyroidism	4 (.54%)
Lymphadenopathy	4 (.54%)
Myalgia	4 (.54%)
Pain Of Skin	4 (.54%)
Paraesthesia	4 (.54%)
Rash Generalised	4 (.54%)
Respiratory Failure	4 (.54%)
Skin Discolouration	4 (.54%)
Viith Nerve Paralysis	4 (.54%)
Weight Increased	4 (.54%)
Abdominal Pain	3 (.41%)
Acarodermatitis	3 (.41%)
Agranulocytosis	3 (.41%)
Anaemia	3 (.41%)
Anaphylactic Shock	3 (.41%)
Anorexia	3 (.41%)
Bile Duct Obstruction	3 (.41%)
Blood Pressure Decreased	3 (.41%)
Bone Marrow Failure	3 (.41%)
Cancer Pain	3 (.41%)
Cardio-respiratory Arrest	3 (.41%)
Hepatic Failure	3 (.41%)
Hyperhidrosis	3 (.41%)
Insomnia	3 (.41%)
Metabolic Acidosis	3 (.41%)
Myelodysplastic Syndrome	3 (.41%)
Myocardial Infarction	3 (.41%)
Nasopharyngitis	3 (.41%)
Pancytopenia	3 (.41%)
Peripheral Coldness	3 (.41%)
Pleural Effusion	3 (.41%)
Respiratory Disorder	3 (.41%)
Serum Sickness	3 (.41%)
Throat Tightness	3 (.41%)
Urticaria	3 (.41%)
Acute Respiratory Distress Syndrome	2 (.27%)
Amenorrhoea	2 (.27%)
Atrial Fibrillation	2 (.27%)
Autoantibody Positive	2 (.27%)
Blood Creatine Increased	2 (.27%)
Blood Lactate Dehydrogenase Increas...	2 (.27%)
Body Temperature Increased	2 (.27%)
Bradycardia	2 (.27%)
Capillary Disorder	2 (.27%)
Cardiovascular Disorder	2 (.27%)
Dialysis	2 (.27%)
Dyspepsia	2 (.27%)
Dysphagia	2 (.27%)
Ear Pain	2 (.27%)
Ejection Fraction Decreased	2 (.27%)
Electrolyte Imbalance	2 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Bexxar, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Bexxar is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Bexxar

What are the most common Bexxar adverse events reported to the FDA?

Epidermal And Dermal Conditions	48 (6.52%)
Respiratory	40 (5.43%)
Gastrointestinal Signs	39 (5.3%)
Neurological	31 (4.21%)
Musculoskeletal And Connective Tiss...	28 (3.8%)
Infections - Pathogen Unspecified	26 (3.53%)
Body Temperature Conditions	25 (3.4%)
Hematology Investigations	25 (3.4%)
Therapeutic And Nontherapeutic Effe...	18 (2.45%)
Decreased And Nonspecific Blood Pre...	15 (2.04%)
Joint	15 (2.04%)
	Show More
Physical Examination Topics	14 (1.9%)
White Blood Cell	14 (1.9%)
Administration Site Reactions	13 (1.77%)
Hepatic And Hepatobiliary	13 (1.77%)
Allergic Conditions	11 (1.49%)
Movement Disorders	11 (1.49%)
Anemias Nonhemolytic And Marrow Dep...	10 (1.36%)
Vascular	10 (1.36%)
Bacterial Infectious	8 (1.09%)
Cardiac And Vascular Investigations	8 (1.09%)
Cardiac Arrhythmias	8 (1.09%)
Muscle	8 (1.09%)
Leukemias	7 (.95%)
Medication Errors	7 (.95%)
Spleen, Lymphatic And Reticulendoth...	7 (.95%)
Viral Infectious	7 (.95%)
Cranial Nerve Disorders	6 (.82%)
Heart Failures	6 (.82%)
Lymphomas	6 (.82%)
Platelet	6 (.82%)
Fatal Outcomes	5 (.68%)
Immunology And Allergy	5 (.68%)
Skin Appendage Conditions	5 (.68%)
Arteriosclerosis, Stenosis, Vascula...	4 (.54%)
Bronchial Disorders	4 (.54%)
Depressed Mood Disorders	4 (.54%)
Headaches	4 (.54%)
Renal And Urinary Tract Investigati...	4 (.54%)
Thyroid Gland	4 (.54%)
Acid-base	3 (.41%)
Angiedema And Urticaria	3 (.41%)
Appetite And General Nutritional	3 (.41%)
Bile Duct	3 (.41%)
Cardiac Disorder Signs	3 (.41%)
Coronary Artery	3 (.41%)
Ectoparasitic	3 (.41%)
Electrolyte And Fluid Balance Condi...	3 (.41%)
Embolism And Thrombosis	3 (.41%)
Enzyme	3 (.41%)
Glucose Metabolism Disorders	3 (.41%)
Hematological And Lymphoid Tissue T...	3 (.41%)
Hepatobiliary	3 (.41%)
Lower Respiratory Tract Disorders	3 (.41%)
Neoplasm Related Morbidities	3 (.41%)
Ocular Infections, Irritations And ...	3 (.41%)
Pleural	3 (.41%)
Sleep Disorders	3 (.41%)
Tissue	3 (.41%)
Urinary Tract Signs	3 (.41%)
Aural	2 (.27%)
Bone Disorders	2 (.27%)
Bone, Calcium, Magnesium And Phosph...	2 (.27%)
Cardiac Valve	2 (.27%)
Central Nervous System Infections A...	2 (.27%)
Gastrointestinal Conditions	2 (.27%)
Gastrointestinal Inflammatory Condi...	2 (.27%)
Gastrointestinal Motility And Defec...	2 (.27%)
Menstrual Cycle And Uterine Bleedin...	2 (.27%)
Miscellaneous And Site Unspecified ...	2 (.27%)
Oral Soft Tissue Conditions	2 (.27%)
Pericardial	2 (.27%)
Renal Disorders	2 (.27%)
Anxiety Disorders	1 (.14%)
Central Nervous System Vascular	1 (.14%)
Chemical Injury And Poisoning	1 (.14%)
Chromosomal Abnormalities And Abnor...	1 (.14%)
Deliria	1 (.14%)
Endocrine Investigations	1 (.14%)
Gallbladder	1 (.14%)
Hematological	1 (.14%)
Investigations, Imaging And Histopa...	1 (.14%)
Lifestyle Issues	1 (.14%)
Metabolic, Nutritional And Blood Ga...	1 (.14%)
Myocardial	1 (.14%)
Peripheral Neuropathies	1 (.14%)
Pulmonary Vascular	1 (.14%)
Sleep Disturbances	1 (.14%)
Soft Tissue Sarcomas	1 (.14%)
Therapeutic Procedures And Supporti...	1 (.14%)
Thoracic Disorders	1 (.14%)
Toxicology And Therapeutic Drug Mon...	1 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Bexxar, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Bexxar is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Bexxar According to Those Reporting Adverse Events

Why are people taking Bexxar, according to those reporting adverse events to the FDA?

Non-hodgkins Lymphoma	111
Drug Use For Unknown Indication	24
Lymphoma	14
Multiple Myeloma	6
Product Used For Unknown Indication	4
B-cell Lymphoma	2
	Show More
Mantle Cell Lymphoma	2
Accidental Exposure	1
Blood Stem Cell Transplant Failure	1
Chemotherapy	1
Immunosuppressant Drug Therapy	1
Diffuse Large B-cell Lymphoma	1
B-cell Small Lymphocytic Lymphoma	1
Skin Lesion	1
B-cell Lymphoma Recurrent	1

Drug Labels

Label	Labeler	Effective
Bexxardosimetric	GlaxoSmithKline LLC	20-AUG-12
Bexxartherapeutic	GlaxoSmithKline LLC	20-AUG-12
Bexxar	GlaxoSmithKline LLC	20-AUG-12

Bexxar Case Reports

What Bexxar safety concerns are being reported by doctors and researchers in the medical literature?

About Results

This report contains aggregated drug side effects and adverse events for Bexxar. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Bexxar.